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Objective: To investigate the reliability of the different methods used in Norway and Russia for detection of diphtheria 
antitoxin. 
Methods: One hundred and twenty-two sera were selected among Russian serum samples previously collected for 
seroepidemiologic studies of diphtheria antitoxin. The sera were selected to cover the total antitoxin range and were 
analyzed by four different antidiphtheria toxin assays: an in vitro toxin neutralization test using Vero cells (in vitro NT), 
an in vivo neutralization test using rabbit skin inoculation (in vivo NT), an indirect enzyme immunoassay (EIA) and a 
passive hemagglutination assay (PHA). The results were expressed according to the international standard as: not 
protected (<0.01 IU/mL), relatively protected (0.01-0.1 IU/mL) or protected (20.1 IU/mL). The sensitivity, specificity and 
inter-rater agreement (K or Kw) of each method were related to the in vitro NT selected as the reference method. 
Results: The in vivo NT test corresponded very well with the in vitro NT in its ability to differentiate between 
protection/relative protection and no protection (sensitivity 97%, specificity 87% and K=0.84). The EIA test showed a 
high sensitivity (96%), but since many sera were categorized as protected rather than not protected, the specificity (30%) 
and inter-rater agreement (K=0.29) were low. The PHA test had a very high specificity (100%) but a low sensitivity (86%). 
Conclusions: The agreement between the two neutralization tests was high. If none of the neutralization assays is 
routinely available, the PHA test can be used to predict the need for vaccination on an individual basis but should not 
be used for seroepidemiologic studies, since the protection rate for diphtheria would be falsely too low, due to the lower 
sensitivity. The indirect EIA test used in this study should not be used routinely. 
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INTRODUCTION 
Diphtheria has become a rare disease in developed 
countries during the last decades. However, it re- 
emerged in Russia in 1990, and an epidemic spread to 
Ukraine the following year [l]. By 1994, all the New 
Independent States (NIS) formerly belonging to the 
Soviet Union had an ongoing epidemic, and neigh- 
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boring countries of the NIS, Norway included, have 
experienced sporadic cases of diphtheria [l-31. 
The re-emergence of diphtheria has demonstrated 
the importance of infection control and immunity 
surveillance. Seroepidemiologic surveillance is depen- 
dent on reliable methods for measuring protective 
levels of hphtheria antitoxin. The earliest method for 
detecting serum antitoxin levels was developed by 
Behring, Ehrlich and Roux (1892-1895). In a sensitive 
assay using skin inoculation of guinea pigs, the ability 
of serum to neutralize the local effect of diphtheria 
toxin was measured by titration [4]. However, despite 
modifications of this technique by Romer and Somogyi 
[5] and Jensen [6], methods requiring animals are not 
easily applied as screening tests. Therefore, different in 
vitro methods have been developed in order to measure 
the degree of protection against diphtheria [7,8]. A 
toxin neutralization test based on Vero cells is now well 
628 
Skogen e t  al:  Detec t i on  of d i p h t h e r i a  a n t i t o x i n  by f o u r  d i f f e r e n t  m e t h o d s  6 2 9  
established [Y] and indirect enzyme immunoassays 
(EIA) have been tried. In Russia, a passive hemag- 
glutination test has been the routine test for many years, 
using the in vivo toxin neutralization assay as the 
reference test. 
In this study we wanted to compare the agreement 
of these four methods, in order to investigate the 
reliability of detecting the true protection level of 
diphtheria antitoxin. 
MATERIALS AND METHODS 
Serum samples 
One hundred and twenty-two serum samples were 
included in the study. The sera belonged to a collection 
of Russian samples used in a previously reported and 
still continuing seroepidemiologic study of diphtheria 
protection [lo]. The sera were selected to cover the 
total normal diphtheria antitoxin range. The male/ 
female ratio was 1.27, and the mean age of the subjects 
was 39.6 years (range 2-85 years). The sera were all 
stored at -20°C, before being analyzed blindly. 
Serologic tests 
Four different diphtheria antitoxin assays were used in 
the study. An in vitro toxin neutralization test (in vitro 
NT) and an indirect EIA were performed at the 
Department of Bacteriology, National Institute of Public 
Health, Oslo, Norway. An in vivo toxin neutralization 
test (in vivo NT) and a passive hemagglutination (PHA) 
assay were performed at the Laboratory of Epidemio- 
logic Surveillance for Diphtheria, G.N. Gabrichevsky 
Institute for Epidemiology and Microbiology, Moscow, 
Russia. 
In vivo toxin neutralization test (in vivo NT) 
The in vivo N T  was performed with minor modi- 
fications according to the method described by Jensen 
[6] and according to the L.A. Tarasevich State Institute 
for Standardization and Control of Medical Bio- 
products, Moscow, Russia. The amount of toxin used 
in the test corresponded to the 1/3000 IU reactive dose 
(LR/3000). LR is the minimal amount of toxin that, 
when mixed with 1/3000 IU antitoxin in a volume of 
0.1 mL, produces a 10-mm-diameter non-necrotic 
erythematous area after 48 h when inoculated intra- 
cutaneously in rabbits (23 kg). For the biological assay, 
serum dilutions were incubated with the toxin for 2 h 
at 37OC, and 0.1 mL of the mixture (containing 
LR/3000) was then inoculated intracutaneously. The 
results were read after 48 h, and the serum antitoxin 
titer was calculated by comparison to standard serum 
inoculated at the same time. The results were expressed 
as IU/mL. 
In vitro toxin neutralization test (in vitro NT) 
The in vitro toxin neutralization assay was based on the 
method described by Miyamura et al. [Y] and per- 
formed as described earlier [lo]. In brief, two-fold 
dilutions of serum were mixed with four times the 
minimal cytotoxic dose of diphtheria toxin (Statens 
Seruminstitut, Copenhagen, Denmark) and incubated 
at 37°C for 1 h before Vero cells (African green monkey 
kidney) were added. An antitoxin-positive control 
serum was run for every 17th serum sample. The pH- 
mediated color of the culture medium, which changed 
from red to yellow, as a result of growing Vero cells, 
was recorded after 5 days of incubation at 37°C. 
The antitoxin level of each sample was determined 
by comparing the color change breakpoint to that 
of a WHO standard (Statens Seruminstitut) analyzed 
simultaneously [lo]. The results were expressed as 
I U / d .  
Enzyme immunoassay 
Flat-bottomed immunoplates (Nunc-immunosorp, 
code 439454, Nunc, Denmark) were coated with 
100 pL (2.5 pg/mL) of diphtheria toxoid (Statens 
Seruminstitut) in phosphate-buffered saline (PBS), pH 
7.2. Following overnight incubation at 37"C, the plates 
were washed three times with PBS containing 0.05% 
Tween-20 (PBST), pH 7.4. One hundred microliters 
of PBST with 0.1% bovine serum albumin was then 
added to each well, and the plates were incubated at 
37°C for 30 min to block unspecific binding sites, and 
then washed three times with PBST. The serum 
samples were diluted 1:50 in PBST, and 100 pL was 
added to duplicate wells. The samples were then 
incubated at 37°C for 2 h, followed by washing three 
times. One hundred microliters of swine antihuman 
IgG conjugated to alkaline phosphatase (Orion Diag- 
nostica, Helsinki, Finland) diluted 1:200 in PBST was 
then added to each well. Following incubation for 2 h 
at 37"C, 100 pL (1 mg/mL) of dinitrophenylphosphate 
(Sigma 104, St Louis, MO, USA) in diethanolamine 
buffer, pH 9.8, was added. The color development was 
stopped after 45 min at room temperature by adding 50 
pL of 4M NaOH, and the plates were read in a 
microplate reader (340 ATC, SLT Laboratory Instru- 
ments, Salzburg, Austria) at 405 nm with 492 nm as the 
reference wavelength. The OD result of each serum 
was transformed to IU/mL by comparing the result to 
a standard curve, obtained by analyzing fourfold dilutions 
of a human reference serum (Statens Seruminstitut), 
using a curve-fit computer program (Soft 2000, SLT 
Laboratory Instruments) connected to the reader. 
Optimization of the test was determined by pre- 
liminary experiments. The lowest detectable antibody 
amount was 0.02 IU/mL. 
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Passive hemagglutination test (PHA) 
The passive hemagglutination test (I. I. Mechnikov/ 
Biomed, Moscow, Russia) was performed according to 
the standard instructions given by the Russian Health 
Authorities [11]. Each serum, diluted 1:5 in isotonic 
saline, was adsorbed with non-sensitized sheep erythro- 
cytes for 24 h at 4OC to remove non-specific agglutinins. 
Each serum was then diluted two-fold in U-bottom 
microtiter wells starting at l:lO, using the dhen t  buffer 
provided by the manufacturer. To each well, containing 
100 pL of dduted serum, 25 pL of a suspension of sheep 
erythrocytes sensitized with diphtheria toxoid was 
added. The plates were stirred gently and stored at 
room temperature for 60 min before the agglutination 
pattern was read. The results were expressed as titers. 
A serum control for the presence of non-specific 
agglutinins was included for each serum, and positive 
controls were included in each run. 
Protection levels 
The antibody amounts detected for the in vivo NT, the 
in vitro NT and the EIA were grouped according to 
the protection level against diphtheria [12]: no pro- 
tection, CO.01 IU/mL (EIA <0.02 IU/mL); relative 
protection, 0.01-0.1 IU/mL (EIA 0.02-0.1 IU/mL); 
or protection, 10 .1  IU/mL. For the PHA test, the 
protection levels related to titer values were based on 
recommendations given by the Russian Health Autho- 
rities: no protection titer 5 10, relative protection titer 
20-80, and protection titer 2160 [11]. 
Statistical methods 
Sensitivity and specificity for each test were calculated 
according to Galen [13], and inter-rater agreement was 
estimated by kappa (K) and weighted kappa (Kw) 
according to Altman [14], with the in vitro NT as the 
reference test (SPSS for Windows, version 8.0, Chicago 
SPSS, Ilhnois, USA). The inter-rater agreement (K and 
Kw) was classified as poor (<0.20), fair (0.21-0.40), 
moderate (0.41-0.60), good (0.61-0.80) or very good 
(0.81-1.00), according to the guidelines given by 
Landis and Koch [ 151 and Altman [ 141. The agreement 
was calculated for two different cut-off levels: between 
no protection and relative protection, and between 
relative protection and protection. 
RESULTS 
The results achieved by the different assays grouped 
according to the degree of protection are shown in 
Tables 1 and 2. By the in vitro NT, 23 sera (18.9%) had 
non-protective levels of antitoxin, 47 (38.5%) had 
relatively protective levels, and 52 (42.6%) protective 
levels. By the in vivo NT, the same number of sera 
showing no protection (18.9%) was found, while a 
higher riumber showed protection (54.9%). Only 
10.7% of the sera showed non-protective levels of 
antitoxin by the EIA, whde as many as 69.7% showed 
protective levels. The highest proportion of sera 
classified as having no protection (30.3%) was found by 
the PHA. By this test, only 38.5% of the sera were 
classified as protected. The agreement between the in 
vitro NT and the in vivo NT expressed by weighted 
kappa (Kw) was good (Kw=0.71, 95% confidence 
interval (CI), 0.57-0.85) (Table 2). Forthe EIA, the Kw 
was moderate (KwzO.43, 95% CI, 0.30-0.55), and for 
the PHA the Kw was good (Kw=0.76, 95% CI, 
0.634.90). 
The highest agreement (K=0.84) was found when 
comparing the two toxin neutralization tests using a 
cut-off of 0.01 I U / d  (Table 3) while the lowest was 
found between the EIA test and the in vitro NT using 
a 0.01 IU/mL cut-off. Also, at a cut-off of 0.1 IU/mL, 
the agreement was lowest between the in vitro NT and 
the EIA. Although the sensitivity of the EIA was 100%, 
the specificity was low (53%) (Table 3). The PHA test 
showed the highest specificity (100%) but the lowest 
sensitivity (86%) (Table 3). 
Table 1 Antibodies against diphtheria toxin for 122 sera examined by four different methods according to level of 
protection against diphtheria [12] 
No protection, Relative Protection, Protection, 
<0.01 IU/mL’ 0.01 to <0.1 IU/mL” 20.1 IU/mL 
Method n % 95% CI n % 95% CI n % 95% CI 
In via0 NTa 23 18.9 11.9-25.8 47 38.5 29.9-47.2 52 42.6 33.8-51.4 
In vivo N T  23 18.9 11.9-25.8 32 26.2 18.4-34.0 67 54.9 46.143.7 
PHA 37 30.3 22.2-38.5 38 31.1 22.9-39.4 47 38.5 29.9-47.2 
“For the EIA test, the cut-off between not protected and relatively protected was 0.02, in accordance with the detection limit of the test (see 
text). 
NT, diphtheria toxin neutdzation test; EIA, enzyme immunoassay (indirect); PHA, passive hemagglutination assay. 
EIA 13 10.7 5.2-16.1 24 19.7 12.6-26.7 85 69.7 61.5-77.8 
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Table 2 Comparison of four different assays for determination of antibodies against diphtheria toxin" with in vitro NT as 
reference assay 
In vitro N T  
Relative 
No protectionb protectionb Protection Total 
Method (n=23) (n=47) (n=52) (n= 122) Kw' 95% CId 
In vivo N T  No protection 20 3 0 23 0.71 0.57-0.85 
Relative protection 3 25 4 32 
Protection 0 19 48 67 
EIA N o  protection 7 6 0 13 0.43 0.30-0.55 
Relative protection 10 14 0 24 
Protection 6 27 52 85 
PHA No protection 23 13 1 37 0.76 0.63-0.90 
Relative protection 0 31 7 38 
Protection 0 3 44 47 
~~~ ~~ 
aNo protection, 10.01 I U / d ,  relative protection, 0.01 to <0.1 I U / d ;  protection, 20.1 I U / d  [12]. 
bFor the EIA test, the cut-off between not protected and relatively protected was 0.02, in accordance with the detection limit of the test (see 
text). 
d95% confidence interval. 
NT, diphtheria toxin neutralization test; EIA, enzyme immunoassay (indirect); PHA, passive hemagglutination assay. 
Weighted Kappa [14]. 
Table 3 Sensitivity, specificity and inter-rater agreement for 122 selected sera using four different antidlphtheria toxin assays, 
with in vitro NT as reference test 
Sensitivity (%) Specificity (%) Agreement (K)' 95% CIb for K 
Cut-off=O.Ol I U / d '  
In vivo N T  97 87 0.84 0.66-1 .00 
0.13-0.46 EIA 96 30 0.29 
PHA 86 1 no 0.70 0.53-0.87 
Cut-off=0.l IU/mL' 
In vivo N T  92 73 0.63 0.46-0.80 
EIA 100 53 0.49 0.34-0.64 
PHA 85 96 0.81 0.64-0.99 
'Kappa [14]. 
h95% confidence interval. 
'No protection, <0.01 I U / d ,  relative protection, 0.01 to <0.1 I U / d ;  protection; 20.1 IU/mL [12]. 
NT, diphtheria toxin neutralization test; EIA, enzyme immunoassay (indirect); PHA, passive hemagglutination assay. 
DISCUSSION 
A reliable test for the detection of immunity to 
diphtheria is important both when performing sero- 
epidemiologic studes and on an individual basis in 
order to investigate the need for diphtheria vaccination 
or for the detection of clinical diphtheria. 
The in vivo NT was the original standard method 
[4]. However, the need for animals makes this test 
difficult to use as a standard routine reference assay. 
Therefore, we decided to use the toxin neutralization 
test on Vero cells in microculture (in vitro NT) as the 
reference method. This is in accordance with the 
recommendation given by the First International 
Meeting of the WHO Laboratory Working Group on 
Diphtheria in 1994 [4]. The agreement (Kw) between 
the two neutralization assays was classified as good. The 
main discrepancy was that 19 of 47 sera (40%) grouped 
as relatively protected by the in vitro NT were grouped 
as protected by the in vivo NT. A high correlation 
between the in vivo and the in vitro NT has also been 
shown by Miyamura et al[9,16], Kriz [17] and Kjeldsen 
et al [18]. 
The EIA test used in this study produced a large 
number of false-positive results. Used in a sero- 
epidemiologic study, this test would give the impression 
that the population was better protected against 
diphtheria than is actually the case. If this test were used 
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to evaluate the need for either basic or booster vaccina- 
tion, many indwiduals who need immunization would 
be falsely judged as protected and thus escape vaccina- 
tion. 
The serum samples included in this study were 
selected to be equally distributed over the total anti- 
body range. In a population with a high vaccine coverage 
against diphtheria, the proportion of protected indi- 
viduals will normally dominate. Although the sensi- 
tivities and the specificities of the different tests in the 
study are independent of the prevalence of antitoxin in 
the population, the inter-rater agreement as measured 
by K is dependent on the proportions of sera classified 
as no protection, relative protection and protection, 
respectively. Thus, the EIA test, which had a high 
agreement with the reference test in the upper part of 
the antibody range (protection) (Table 2), would have 
a hlgher inter-rater agreement with the reference test 
than measured in our study, when used in a sero- 
epidemiologic study on a highly vaccinated population. 
Despite this fact, we cannot recommend this indirect 
EIA test. The tendency towards false-positive results by 
EIA has also been shown in previous studies by Knight 
et al[7] and Mellville-Smith and Balfour [8]. However, 
Hendriksen et al[19] have described a modified version 
of the EIA test which has shown higher correlation 
with the neutralization test, and recently Kristiansen et 
al [20] have described an EIA test using the double 
antigen principle for detection of diphtheria antibodies 
that corresponds well with an in vitro NT. 
Due to rapidity, low cost and no need for special 
equipment, the PHA is the most frequently used 
routine assay in Russia, both in the pre-epidemic 
period and during the epidemic, where it is used for 
monitoring immunity. Seroepidemiologic studies 
conducted in the Soviet Union during the 1980s and 
the beginning of the 1990s, using the PHA as the test 
assay, showed a high prevalence of people lacking 
immunity to the diphtheria toxin [21-241. These 
studies supplied evidence for some of the reasons for 
the resurgence of diphtheria, such as low vaccine 
coverage among children and adults and waning of 
vaccine-induced immunity. 
The overall strength of agreement between the 
PHA assay and the in vitro NT was classified as good 
(Kw=0.76), and the strength of the agreement using 
cut-offO.O1 I U / d  and 0.1 I U / d  was good (K=0.70) 
and very good (K=0.81), respectively. However, the 
main limitation of the PHA was the low sensitivity. Of 
the 47 sera belonging to the relative protection group 
by the in vitro NT, 13 sera (28%) showed no protection 
by the PHA, and one of 52 sera (2%) in the protection 
group also tested negative by the PHA. This tendency 
to underestimate low concentrations of diphtheria 
antibohes by the PHA has also been shown by 
Simonsen [25] and Galazka and Abgarowicz [26]. In 
seroepidemiologic studies based on the PHA test, the 
proportion of individuals found to be unprotected 
against diphtheria would be falsely too hlgh, giving the 
impression that the population is more susceptible to 
the spread of diphtheria than is actually the case. In a 
previous study comparing antibody prevalences among 
Norwegians and Russians, the protection levels among 
Russians was not significantly different from that 
detected among Norwegians [lo]. Nevertheless, it is a 
fact that the diphtheria epidemic spread in Russia and 
not in Norway. Therefore, lack of protection against 
diphtheria seem to be only one factor necessary for the 
spread of the epidemic. 
When one of the neutrahation tests is not 
routinely avadable, the PHA can be used for routine 
testing bearing in mind that when it is used for 
seroepidemiologic purposes the protection rate will be 
hgher than what is actually measured. When the PHA 
is used to predict the need for individual vaccination, 
almost all subjects with insufficient immunity, i.e. 
subjects who would have been identified as relatively 
protected or non-protected by the in vitro NT, will be 
recommended for vaccination. 
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